vs
BillionToOne, Inc.（BLLN）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是STEM, INC.的1.8倍（$83.5M vs $47.1M），BillionToOne, Inc.净利率更高（6.8% vs -33.9%，领先40.7%），BillionToOne, Inc.同比增速更快（117.4% vs -15.6%）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
BLLN vs STEM — 直观对比
营收规模更大
BLLN
是对方的1.8倍
$47.1M
营收增速更快
BLLN
高出133.0%
-15.6%
净利率更高
BLLN
高出40.7%
-33.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $47.1M |
| 净利润 | $5.7M | $-16.0M |
| 毛利率 | 69.9% | 48.9% |
| 营业利润率 | 11.5% | -17.7% |
| 净利率 | 6.8% | -33.9% |
| 营收同比 | 117.4% | -15.6% |
| 净利润同比 | 138.3% | 68.8% |
| 每股收益（稀释后） | $0.10 | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNSTEM
| Q4 25 | — | $47.1M | ||
| Q3 25 | $83.5M | $38.2M | ||
| Q2 25 | — | $38.4M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | $45.1M | $55.8M | ||
| Q3 24 | $38.4M | $29.3M | ||
| Q2 24 | — | $34.0M | ||
| Q1 24 | — | $25.5M |
净利润BLLNSTEM
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $5.7M | $-23.8M | ||
| Q2 25 | — | $202.5M | ||
| Q1 25 | — | $-25.0M | ||
| Q4 24 | $-11.5M | $-51.1M | ||
| Q3 24 | $-14.9M | $-148.3M | ||
| Q2 24 | — | $-582.3M | ||
| Q1 24 | — | $-72.3M |
毛利率BLLNSTEM
| Q4 25 | — | 48.9% | ||
| Q3 25 | 69.9% | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | 57.1% | -4.4% | ||
| Q3 24 | 52.6% | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
营业利润率BLLNSTEM
| Q4 25 | — | -17.7% | ||
| Q3 25 | 11.5% | -33.6% | ||
| Q2 25 | — | -34.8% | ||
| Q1 25 | — | -65.0% | ||
| Q4 24 | 17.0% | -84.4% | ||
| Q3 24 | -32.9% | -493.2% | ||
| Q2 24 | — | -1705.5% | ||
| Q1 24 | — | -267.0% |
净利率BLLNSTEM
| Q4 25 | — | -33.9% | ||
| Q3 25 | 6.8% | -62.2% | ||
| Q2 25 | — | 527.8% | ||
| Q1 25 | — | -76.9% | ||
| Q4 24 | -25.5% | -91.6% | ||
| Q3 24 | -38.8% | -506.3% | ||
| Q2 24 | — | -1712.6% | ||
| Q1 24 | — | -283.9% |
每股收益（稀释后）BLLNSTEM
| Q4 25 | — | $-4.40 | ||
| Q3 25 | $0.10 | $-2.84 | ||
| Q2 25 | — | $-1.79 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | $-1.13 | $-15.29 | ||
| Q3 24 | $-1.47 | $-18.24 | ||
| Q2 24 | — | $-71.81 | ||
| Q1 24 | — | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $48.9M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $-249.4M |
| 总资产 | $327.5M | $308.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNSTEM
| Q4 25 | — | $48.9M | ||
| Q3 25 | $195.2M | $43.1M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | — | $58.6M | ||
| Q4 24 | $191.5M | $56.3M | ||
| Q3 24 | — | $75.4M | ||
| Q2 24 | — | $89.6M | ||
| Q1 24 | — | $112.8M |
总债务BLLNSTEM
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNSTEM
| Q4 25 | — | $-249.4M | ||
| Q3 25 | $-239.5M | $-235.7M | ||
| Q2 25 | — | $-214.1M | ||
| Q1 25 | — | $-417.5M | ||
| Q4 24 | $-251.7M | $-398.4M | ||
| Q3 24 | $-242.9M | $-344.1M | ||
| Q2 24 | — | $-203.2M | ||
| Q1 24 | — | $371.6M |
总资产BLLNSTEM
| Q4 25 | — | $308.9M | ||
| Q3 25 | $327.5M | $362.6M | ||
| Q2 25 | — | $379.2M | ||
| Q1 25 | — | $405.1M | ||
| Q4 24 | $302.1M | $437.4M | ||
| Q3 24 | — | $537.8M | ||
| Q2 24 | — | $691.5M | ||
| Q1 24 | — | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | — |
| 自由现金流率自由现金流/营收 | 7.7% | — |
| 资本支出强度资本支出/营收 | 8.8% | — |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BLLNSTEM
| Q4 25 | — | $8.2M | ||
| Q3 25 | $13.8M | $11.4M | ||
| Q2 25 | — | $-21.3M | ||
| Q1 25 | — | $8.5M | ||
| Q4 24 | — | $-14.7M | ||
| Q3 24 | — | $-9.4M | ||
| Q2 24 | — | $-11.9M | ||
| Q1 24 | — | $-621.0K |
自由现金流BLLNSTEM
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率BLLNSTEM
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BLLNSTEM
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率BLLNSTEM
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
STEM
暂无分部数据
